DCIT vs Mahindra CIE Automotive Ltd.

Introduction

The Income Tax Appellate Tribunal (ITAT), Mumbai Bench ā€œDā€, delivered a significant ruling on December 8, 2020, in the case of DCIT v. M/s. Mahindra CIE Automotive Ltd. (formerly Mahindra Forgings Ltd.), addressing two pivotal issues under the Income Tax Act, 1961. The primary dispute centered on the deductibility of Employee Stock Option Plan (ESOP) expenses under Section 37(1) of the Act, with a secondary issue concerning interest disallowance under Section 36(1)(iii). The Tribunal, comprising Judicial Member Shri C.N. Prasad and Accountant Member Shri S. Rifaur Rahman, upheld the Commissioner of Income Tax (Appeals) [CIT(A)]’s decision, reinforcing that ESOP discounts constitute legitimate employee remuneration rather than notional capital expenditures. This commentary provides a deep legal analysis of the Tribunal’s reasoning, its alignment with judicial precedents, and the implications for corporate tax planning.

Facts of the Case

The Revenue filed six appeals (ITA Nos. 2320 to 2325/MUM/2019) for Assessment Years (A.Y.) 2008-09 to 2013-14 against the orders of the Ld. CIT(A)-13, Mumbai. The common ground for A.Y. 2008-09 and 2009-10 involved the deletion of disallowance made by the Assessing Officer (AO) regarding ESOP expenses. The AO had disallowed the ESOP discount of Rs. 4,62,26,300/-, treating it as a notional expense incurred in relation to the issue of shares to employees, resulting in an increase in capital—thus not allowable under Section 37(1). The AO relied on Supreme Court rulings in Punjab State Industrial Development Corp. Ltd. (1997) 225 ITR 792 (SC) and Brooke Bond India Ltd. (1997) 225 ITR 798 (SC), as well as the Delhi Tribunal’s decision in Ranbaxy Laboratories Ltd. v. ACIT [124 TTJ 771 (2009)]. The CIT(A) reversed this disallowance, following the Bangalore Special Bench in M/s. Biocon Limited [115 TTJ 649], which held that ESOP discount is an ascertained liability deductible under Section 37(1). The Revenue appealed, arguing that the CIT(A) erred in law.

Reasoning of the Tribunal

The Tribunal’s reasoning, as articulated by Judicial Member C.N. Prasad, was concise yet legally robust, focusing on the binding nature of the Special Bench decision in Biocon Limited. The analysis unfolded in three key layers:

1. ESOP Expenses as Employee Remuneration, Not Capital Expenditure:
The Tribunal rejected the Revenue’s contention that ESOP discount is a notional loss or a short receipt of share premium. Citing Biocon Limited, the Tribunal emphasized that the primary object of issuing ESOPs is not to raise capital but to secure employee services. The discount on shares is a substitute for cash incentives, forming part of the employee’s remuneration package. The Special Bench had clarified that ā€œdiscount on premium under ESOP is simply a mode of compensating employees for their continued services to the company and is a part of their remuneration.ā€ This aligns with Section 37(1), which allows deduction for expenditure laid out wholly and exclusively for business purposes. The Tribunal noted that Section 37(1) does not restrict expenditure to cash outflows; under Section 43(2), ā€œpaidā€ includes incurred liability. Thus, the ESOP discount, though quantified later, is an ascertained liability during the vesting period, not a contingent one.

2. Distinguishing Supreme Court Precedents:
The Revenue relied on Punjab State Industrial Development Corp. Ltd. and Brooke Bond India Ltd., where the Supreme Court held that expenditure resulting in an increase in capital is not deductible. The Tribunal, however, distinguished these cases, noting that they involved capital receipts or expenditures directly linked to capital structure. In contrast, ESOP discount is an employee cost incurred for business operations, not a capital transaction. The Special Bench in Biocon had explicitly stated that ā€œby no stretch of imagination, such discount can be described as either a short capital receipt or a capital expenditure.ā€ The Tribunal thus found the Revenue’s reliance on these precedents misplaced.

3. Rejection of Notional Loss Argument:
The Revenue argued, based on Ranbaxy Laboratories Ltd., that issuing shares below market price results in a notional loss, not an actual expenditure. The Tribunal countered by adopting the Biocon reasoning: the liability for ESOP discount is incurred at the end of each year during the vesting period, and it is quantified when employees exercise options. This is not a notional loss but a real cost of compensating employees. The Special Bench had held that ā€œthe discount on ESOP is an ascertained liability and not a contingent liability,ā€ making it deductible under Section 37(1). The Tribunal further noted that the CIT(A) had correctly applied this principle, along with decisions from the Mumbai benches in DCIT v. Kotak Mahindra Bank Ltd [89 taxmann.com 223 (Mum)] and Accenture Services Pvt. Ltd. [2010 TIOL 409 ITAT (Mum)], and the Madras High Court in CIT v. PVP Ventures Limited.

4. Interest Disallowance Under Section 36(1)(iii):
Although the primary focus was on ESOP expenses, the Tribunal also addressed the Revenue’s appeal on interest disallowance. The CIT(A) had allowed the deduction, finding no direct nexus between borrowed funds and capital work-in-progress. The Tribunal upheld this, relying on the assessee’s own case precedent, which established that without proven nexus, interest on borrowed funds is deductible under Section 36(1)(iii). This part of the ruling reinforces the principle that interest capitalization requires a clear link to capital assets.

Conclusion

The ITAT’s ruling in Mahindra CIE Automotive Ltd. is a landmark affirmation of the deductibility of ESOP expenses under Section 37(1). By following the Special Bench in Biocon Limited, the Tribunal provided clarity that ESOP discounts are legitimate employee costs, not notional or capital expenditures. This decision reduces litigation risks for corporates implementing ESOPs, aligning tax treatment with accounting standards and SEBI guidelines. The dismissal of the Revenue’s appeal on interest disallowance further underscores the need for factual nexus in tax disputes. For tax practitioners, this case serves as a critical precedent for structuring employee compensation and defending ESOP deductions in assessment orders.

Frequently Asked Questions

What is the key takeaway from this ITAT ruling on ESOP expenses?
The ITAT held that ESOP discount is an allowable deduction under Section 37(1) as employee remuneration, not a notional or capital expenditure. It must be spread over the vesting period and is an ascertained liability, not contingent.
How does this ruling impact corporate tax planning for ESOPs?
Corporates can now confidently claim ESOP discounts as business expenses, reducing taxable income. The ruling aligns with accounting standards, minimizing disputes with tax authorities.
Why did the Tribunal reject the Revenue’s reliance on Supreme Court cases like Punjab State Industrial Development Corp.?
The Tribunal distinguished those cases as involving capital receipts, whereas ESOP discount is a cost for employee services, not a capital transaction. The Biocon Special Bench had already clarified this distinction.
What is the significance of the interest disallowance part of the ruling?
The Tribunal upheld the CIT(A)’s decision that interest on borrowed funds is deductible under Section 36(1)(iii) unless there is a direct nexus to capital work-in-progress. This reinforces the need for evidence in such claims.
Does this ruling apply to all assessment years?
Yes, the ruling covers A.Y. 2008-09 to 2013-14, but its principles are applicable to any year where ESOP expenses are claimed, subject to compliance with Section 37(1) conditions.

Want to read the full judgment?

Access Full Analysis & Official PDF →

Shopping Cart